{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-025697","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2022-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.502898+00:00","generated_at":"2026-06-27T12:22:25.534495+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Reneo Pharmaceuticals CFO Vineet R. Jindal resigns, effective March 31, 2022","bullets":["CFO Vineet R. Jindal notified resignation on Jan 28, 2022; effective March 31, 2022.","Separation agreement includes 9 months base salary severance ($385k/year), 12 months COBRA.","Equity vesting accelerated by 12 months; consulting engagement offered post-separation at $375/hour for 12 months.","No replacement CFO named; Jindal to continue service until separation date."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-025697","json":"https://secwatch.observer/filing/0001193125-22-025697.json","markdown":"https://secwatch.observer/filing/0001193125-22-025697.md","text":"https://secwatch.observer/filing/0001193125-22-025697.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312522025697/0001193125-22-025697-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312522025697/d304619d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T12:22:25.534495+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1dd9b8723a","claim":"Vineet R. Jindal resigned as Chief Financial Officer at OnKure Therapeutics, Inc..","evidence_excerpt":"On January 28, 2022, Vineet R. Jindal notified Reneo Pharmaceuticals, Inc. (the “Company”) of his intention to resign from his position as the Company’s Chief Financial Officer, effective as of March 31, 2022 (the “Separation Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312522025697/0001193125-22-025697-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}